Verrica Pharmaceuticals Inc. (VRCA) Dividend History

Verrica Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing dermatology solutions. The company's lead products target FDA-approved indications for the treatment of skin conditions caused by viruses, such as molluscum contagiosum and common warts. Verrica aims to address unmet medical needs with innovative and well-tolerated therapies for dermatological issues.

10 North High Street, West Chester, PA, 19380
Phone: 484-453-3300
Website: https://www.verrica.com

Dividend History

Verrica Pharmaceuticals Inc. currently does not pay dividends

Company News

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

Verrica Pharmaceuticals announced the acceptance of two abstracts featuring positive preliminary results from a Phase 2 study of its investigational therapy VP-315 for the treatment of basal cell carcinoma. The data showed promising safety, tolerability, and antitumor efficacy.

GlobeNewswire Inc.
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

Verrica Pharmaceuticals reported Q2 2024 financial results, including $4.9M in YCANTH revenue and positive preliminary results from a Phase 2 study of VP-315 for basal cell carcinoma. The company also announced progress in its common warts program and expansion of YCANTH distribution.

GlobeNewswire Inc.
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

- Dormer Labs has discontinued the sale of all cantharidin-containing products into the United States

GlobeNewswire Inc.
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

Global pivotal Phase 3 clinical trial would be conducted jointly by Verrica and Torii Pharmaceutical; trial expected to begin in the 1st half of 2025

GlobeNewswire Inc.
Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Roth MKM cut the price target for Roblox Corporation (NYSE:RBLX) from $55 to $35. Roth MKM analyst Eric Handler downgraded the stock from Buy to Neutral. Roblox shares fell 1.6% to close at $30.96 on Monday. See how other analysts view this stock. Needham boosted the price target for Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) from $8 to $16. Needham analyst Serge Belanger maintained a Buy rating. Verrica Pharmaceuticals shares jumped 19.5% to close at $9.56 on Monday. See how other analysts view this stock. Baird cut Fortrea Holdings Inc. (NASDAQ:FTRE) price target from $45 to $36. Baird analyst Eric Coldwell upgraded the stock from Neutral to Outperform. Fortrea ...Full story available on Benzinga.com

Benzinga

Featured Companies: AGYS AIR FTRE NTRA PLNT RBLX SAM

Dividend data last updated 06/08/2025 00:07:15 UTC